2/26
10:12 pm
bioa
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
Low
Report
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
2/25
08:00 am
bioa
BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.
Low
Report
BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.
2/19
05:11 pm
bioa
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/19
04:30 pm
bioa
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/11
02:41 am
bioa
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
2/11
02:39 am
bioa
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Low
Report
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
2/6
06:23 am
bioa
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Medium
Report
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
2/6
06:17 am
bioa
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Medium
Report
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
2/4
10:15 am
bioa
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
Low
Report
BioAge Labs (NASDAQ:BIOA) was given a new $23.00 price target on by analysts at Morgan Stanley.
2/3
03:37 am
bioa
1/29
06:16 am
bioa
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
BioAge Labs (NASDAQ:BIOA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/27
07:01 am
bioa
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
BioAge Labs (NASDAQ:BIOA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/26
04:13 pm
bioa
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Medium
Report
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
1/26
03:07 am
bioa
Medium
Report
1/21
10:30 pm
bioa
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
Medium
Report
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
1/20
04:18 pm
bioa
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
Low
Report
BioAge Labs plans up to $75M public stock offering; shares down [Seeking Alpha]
1/20
04:01 pm
bioa
BioAge Announces Proposed Public Offering
Low
Report
BioAge Announces Proposed Public Offering
1/20
09:00 am
bioa
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Medium
Report
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
1/18
01:00 am
bioa
1/12
09:00 am
bioa
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
High
Report
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
1/10
01:07 am
bioa
High
Report
1/6
06:22 am
bioa
BLA for subcutaneous formulation of Leqembi® accepted in China
High
Report
BLA for subcutaneous formulation of Leqembi® accepted in China
12/13
10:47 am
bioa
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
Medium
Report
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
12/8
06:44 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list
12/8
06:42 pm
bioa
Leqembi included in China's commercial insurance innovative drug list
Medium
Report
Leqembi included in China's commercial insurance innovative drug list